Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04777110
Other study ID # ESK-ECT20210222
Secondary ID
Status Not yet recruiting
Phase Early Phase 1
First received
Last updated
Start date August 2021
Est. completion date December 2022

Study information

Verified date July 2021
Source First Affiliated Hospital of Chongqing Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A multicenter, randomized, controlled, single blind clinical trial on the efficacy and safety of esmketamine injection in electroconvulsive therapy Objective to evaluate the efficacy and safety of esmketamine injection in the treatment of non convulsive electroconvulsive therapy Participants: Patients with depression receiving MECT The research drug was esketamine injection The study design was a multicenter, randomized, single blind, parallel controlled trial 25 mg / kg as the experimental group. The normal saline group was the control group (0.05 ml / kg). The sample size was estimated according to the main efficacy index (remission rate) of this study. It was assumed that the remission rate of the esketamine injection group was better than that of the control group. The parameters were set as test level α = 0.05, unilateral, β = 0.8, the cut-off value was 6%, the experimental group: the control group was 1:1, according to the results of previous clinical trials and combined with literature, the remission rate of the control group was 69%, 159 cases in each group, considering the 20% shedding rate, 198 cases in the experimental group and 198 cases in the control group were selected. 1. experimental group The patients were given intravenous injection of 0.25 mg / kg esketamine, 1.5 mg / kg propofol and 1 mg / kg succinylcholine in turn. After anesthesia, the patients were given electroconvulsive therapy 2. In the control group The patients were given 0.05ml/kg of normal saline, 1.5mg/kg of propofol and 1mg / kg of succinylcholine. After anesthesia, the patients were given electroconvulsive therapy Efficacy evaluation 1. Main efficacy indicators Remission rate of depressive symptoms after MECT treatment Remission was defined as two consecutive hdrs-24 scores ≤ 10 after receiving MECT Definition rate of remission rate: the proportion of patients with remission of depressive symptoms in this group


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 396
Est. completion date December 2022
Est. primary completion date August 2022
Accepts healthy volunteers No
Gender All
Age group 16 Years to 45 Years
Eligibility Inclusion Criteria: 1. Depressed patients receiving MECT for the first time; 2. 16=age=45 years old, no gender limit; 3. The ASA score is I or II; 4. Meet the diagnostic criteria for depression established by APA, and the Hamilton Depression Rating Scale (HDRS-24) score = 35 points; 5. The depressive episode lasts at least 2 weeks; 6. Clearly understand and voluntarily participate in the study, and sign an informed consent form. Exclusion Criteria: 1. Combined with serious physical diseases, such as uncontrolled hypertension, coronary heart disease, intracranial vascular malformations, asthma attacks, severe liver and kidney dysfunction, etc. 2. There are foreign bodies in the body: such as pacemakers, intracranial electrodes, etc. 3. Those with a history of epilepsy 4. Those who are taking reserpine 5. Acute and systemic infectious diseases, moderate or higher fever 6. History of manic episodes 7. Those who are allergic to anesthetics and muscle relaxants 8. Pregnant women 9. Glaucoma 10. Bipolar disorder, or other mental illnesses, mental retardation 11. Those who judged by the physician in charge to be unsuitable for MECT treatment 12. History of drug abuse

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Esketamine
The main anesthesiologist standing on the right side of the patient injects esketamine (0.25 mg/kg) sequentially, and then propofol (1.5 mg/kg) is injected 1 minute later for 30 s;
Other:
Saline
The main anesthesiologist standing on the right side of the patient injects saline (0.05ml/kg) sequentially, and then propofol (1.5 mg/kg) is injected 1 minute later, the injection time is 30 s

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
First Affiliated Hospital of Chongqing Medical University

Outcome

Type Measure Description Time frame Safety issue
Primary Relief rate of depressive symptoms after MECT treatment After the patient received MECT treatment, the HDRS-24 score = 10 points for two consecutive times immediately after the end of each ECT procedure
Secondary HDRS-24 score after each MECT HDRS-24 score after each MECT Immediately after the end of ECT, four months and six months after the end of the entire treatment course
Secondary Treatment response rate Response is defined as two consecutive HDRS-24 scores = 50% before treatment after receiving MECT treatment. Effectiveness is defined as the proportion of patients in the group that are treated effectively through treatment completion, an average of 18 days
Secondary Severe suicidal tendency elimination rate Severe suicidal tendency is defined as the suicide item score in HDRS-24 = 3 points. The elimination rate of severe suicidal tendency was defined as the proportion of patients with suicide score=0 after treatment in the proportion of patients with severe suicidal tendency through treatment completion, an average of 18 days
Secondary Treatment re-ignition rate Re-ignition is defined as an increase in HDRS-24 score of = 10 points within 4 months of patients in remission. The re-ignition rate is defined as the proportion of re-ignition patients in remission patients. within 4 months of patients in remission
Secondary Treatment recurrence rate The HDRS-24 score increased by =10 points after 4 months for patients whose recurrence is positioned as remission. The recurrence rate is defined as the proportion of relapsed patients in remission. up to 4 months
Secondary Changes in cognitive function Montreal Cognitive Scale (MoCA) assessment Immediately after the end of ECT, four months and six months after the end of the entire treatment course
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A